Preclinical studies demonstrate that KOR activation promotes oligodendrocyte precursor cell (OPC) differentiation and remyelination, leading to functional recovery in experimental MS models (Du et al., 2016; Tangherlini et al., 2019; Thell et al., 2016). Here, OPRK1 is linked to myeloid sarcoma.